Cross-sectional relations of serum aldosterone and urine sodium excretion to urinary albumin excretion in a community-based sample

Kidney International

Volumn 69, Issue 11, 2006, Pages 2064-2069

  Fox, C S ^a,b,c   Larson, M G ^a,d   Hwang, S J ^a   Leip, E P ^d   Rifai, N ^b   Levy, D ^a,c,e   Benjamin, E J ^a,e   Murabito, J M ^a,e   Meigs, J B ^f   Vasan, R S ^a,e  

^a FRAMINGHAM HEART STUDY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d Boston University   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Aldosterone; Epidemiology; Framingham Heart Study; Urinary albumin excretion; Urine sodium

Indexed keywords

ALBUMIN; ALDOSTERONE; CREATININE; SODIUM;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; FEMALE; HUMAN; KIDNEY INJURY; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEINURIA; RENOVASCULAR DISEASE; SODIUM EXCRETION; SODIUM INTAKE; SODIUM URINE LEVEL;

ALBUMINURIA; ALDOSTERONE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; SODIUM;

EID: 33745282934     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000378     Document Type: Article

References (58)

1. Adler AI, Stevens RJ, Manley SE et al. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-232.
2. Nelson RG, Bennett PH, Beck GJ et al. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N Engl J Med 1996; 335: 1636-1642.
3. Peterson JC, Adler S, Burkart JM et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123: 754-762.
4. Maschio G, Alberti D, Janin G et al. Effect of the angiotensin- converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334: 939-945.
5. Hostetter TH, Rennke HG, Brenner BM. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982; 72: 375-380.
6. Hostetter TH, Troy JL, Brenner BM. Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int 1981; 19: 410-415.
7. King AJ, Troy JL, Anderson S et al. Nitric oxide: a potential mediator of amino acid-induced renal hyperemia and hyperfiltration. J Am Soc Nephrol 1991; 1: 1271-1277.
8. Hiragushi K, Sugimoto H, Shikata K et al. Nitric oxide system is involved in glomerular hyperfiltration in Japanese normo- and micro-albuminuric patients with type 2 diabetes. Diabetes Res Clin Pract 2001; 53: 149-159.
9. Apakkan AS, Ozmen B, Ozmen D et al. Serum and urinary nitric oxide in Type 2 diabetes with or without microalbuminuria: relation to glomerular hyperfiltration. J Diabetes Complicat 2003; 17: 343-348.
10. De Vriese AS, Stoenoiu MS, Elger M et al. Diabetes-induced microvascular dysfunction in the hydronephrotic kidney: role of nitric oxide. Kidney Int 2001; 60: 202-210.
11. Sugimoto H, Shikata K, Matsuda M et al. Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy. Diabetologia 1998; 41: 1426-1434.
12. Cadnapaphornchai MA, Ohara M, Morris Jr KG et al. Chronic NOS inhibition reverses systemic vasodilation and glomerular hyperfiltration in pregnancy. Am J Physiol Renal Physiol 2001; 280: F592-F598.
13. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K et al. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989; 32: 219-226.
14. Gschwend S, Pinto-Sietsma SJ, Buikema H et al. Impaired coronary endothelial function in a rat model of spontaneous albuminuria. Kidney Int 2002; 62: 181-191.
15. Verrotti A, Greco R, Basciani F et al. von Willebrand factor and its propeptide in children with diabetes. Relation between endothelial dysfunction and microalbuminuria. Pediatr Res 2003; 53: 382-386.
16. Pedrinelli R, Dell'Omo G, Penno G, Mariani M. Non-diabetic microalbuminuria, endothelial dysfunction and cardiovascular disease. Vasc Med 2001; 6: 257-264.
17. Huvers FC, De Leeuw PW, Houben AJ et al. Endothelium-dependent vasodilatation, plasma markers of endothelial function, and adrenergic vasoconstrictor responses in type 1 diabetes under near-normoglycemic conditions. Diabetes 1999; 48: 1300-1307.
18. Yu HC, Burrell LM, Black MJ et al. Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation 1998; 98: 2621-2628.
19. Benstein JA, Feiner HD, Parker M, Dworkin LD. Superiority of salt restriction over diuretics in reducing renal hypertrophy and injury in uninephrectomized SHR. Am J Physiol 1990; 258(6 Part 2): F1675-F1681.
20. Hertzan-Levy S, Fish R, Skutelsky E et al. Glomerular basement membrane anionic sites in adriamycin nephropathy: effect of saline loading and nitric oxide modulation. Nephron 2000; 84: 354-361.
21. Hertzan-Levy S, Skutelsky E, Arad T et al. Glomerular basement membrane polyanion distribution and nitric oxide in spontaneous hypertensive rats: effects of salt loading and antihypertensive therapy with propranolol. Am J Hypertens 2000; 13: 838-845.
22. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996; 98: 1063-1068.
23. Quan ZY, Walser M, Hill GS. Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney Int 1992; 41: 326-333.
24. Rocha R, Chander PN, Zuckerman A, Stier Jr CT. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999; 33(1 Part 2): 232-237.
25. Rocha R, Stier Jr CT, Kifor I et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000; 141: 3871-3878.
26. Feria I, Pichardo I, Juarez P et al. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 2003; 63: 43-52.
27. du CG, Ribstein J, Mimran A. Dietary sodium and target organ damage in essential hypertension. Am J Hypertens 2002; 15: 222-229.
28. Weir MR, Dengel DR, Behrens MT, Goldberg AP. Salt-induced increases in systolic blood pressure affect renal hemodynamics and proteinuria. Hypertension 1995; 25: 1339-1344.
29. Bigazzi R, Bianchi S, Baldari D et al. Microalbuminuria in salt-sensitive patients. A marker for renal and cardiovascular risk factors. Hypertension 1994; 23: 195-199.
30. Nesovic M, Stojanovic M, Nesovic MM et al. Microalbuminuria is associated with salt sensitivity in hypertensive patients. J Hum Hypertens 1996; 10: 573-576.
31. Verhave JC, Hillege HL, Burgerhof JG et al. Sodium intake affects urinary albumin excretion especially in overweight subjects. J Intern Med 2004; 256: 324-330.
32. Elliott P, Stamler J, Nichols R et al. Intersalt revisited: further analyses of 24 h sodium excretion and blood pressure within and across populations. Intersalt Cooperative Research Group. BMJ 1996; 312: 1249-1253.
33. Luft FC, Fineberg NS, Sloan RS. Estimating dietary sodium intake in individuals receiving a randomly fluctuating intake. Hypertension 1982; 4: 805-808.
34. Kumanyika SK, Hebert PR, Cutler JA et al. Feasibility and efficacy of sodium reduction in the trials of hypertension prevention, phase I. Trials of Hypertension Prevention Collaborative Research Group. Hypertension 1993; 22: 502-512.
35. Blasi ER, Rocha R, Rudolph AE et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003; 63: 1791-1800.
36. Boero R, Pignataro A, Quarello F. Salt intake and kidney disease. J Nephrol 2002; 15: 225-229.
37. Yamada SS, Sassaki AL, Fujihara CK et al. Effect of salt intake and inhibitor dose on arterial hypertension and renal injury induced by chronic nitric oxide blockade. Hypertension 1996; 27: 1165-1172.
38. Chen PY, Sanders PW. -arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats. J Clin Invest 1991; 88: 1559-1567.
39. Daviglus ML, Greenland P, Stamler J et al. Relation of nutrient intake to microalbuminuria in nondiabetic middle-aged men and women: International Population Study on Macronutrients and Blood Pressure (INTERMAP). Am J Kidney Dis 2005; 45: 256-266.
40. Rocha R, Chander PN, Khanna K et al. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998; 31(1 Part 2): 451-458.
41. Nathan DM, Rosenbaum C, Protasowicki VD. Single-void urine samples can be used to estimate quantitative microalbuminuria. Diabetes Care 1987; 10: 414-418.
42. Flack JM, Grimm Jr RH, Staffileno BA et al. New salt-sensitivity metrics: variability-adjusted blood pressure change and the urinary sodium-to-creatinine ratio. Ethn Dis 2002; 12: 10-19.
43. Correa P, Montes G, Cuello C et al. Urinary sodium-to-creatinine ratio as an indicator of gastric cancer risk. Natl Cancer Inst Monogr 1985; 69: 121-123.
44. Arnlov J, Evans JC, Meigs JB et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005; 112: 969-975.
45. Gerstein HC, Mann JF, Yi Q et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-426.
46. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet 1988; 2: 530-533.
47. Spoelstra-de Man AM, Brouwer CB, Stehouwer CD, Smulders YM. Rapid progression of albumin excretion is an independent predictor of cardiovascular mortality in patients with type 2 diabetes and microalbuminuria. Diabetes Care 2001; 24: 2097-2101.
48. Roest M, Banga JD, Janssen WM et al. Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women. Circulation 2001; 103: 3057-3061.
49. Valmadrid CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 2000; 160: 1093-1100.
50. Stehouwer CD, Gall MA, Twisk JW et al. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 2002; 51: 1157-1165.
51. Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989; 36: 272-279.
52. Feinleib M, Kannel WB, Garrison RJ et al. The framingham offspring study. Design and preliminary data. Prev Med 1975; 4: 518-525.
53. Kannel WB, Feinleib M, McNamara PM et al. An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol 1979; 110: 281-290.
54. Bakker AJ. Detection of microalbuminuria. Receiver operating characteristic curve analysis favors albumin-to-creatinine ratio over albumin concentration. Diabetes Care 1999; 22: 307-313.
55. Cupples LA, D'Agostino RB. Some risk factors related to the annual incidence of cardiovascular disease and death using pooled repeated biennial measurements: Framingham Study, 30-year follow-up. In: Kannel WB, Polf PA, Garrison RJ (eds). The Framingham Heart Study. An Epidemiological Investigation of Cardiovascular Disease. Government Printing Office: Washington, DC, 1987 NIH Publication 87-203, section 34.
56. Kleinbaum DG KL, Muller KE. Applied Regression Analysis and Other Multivariable Methods, 2nd edn. PWS-Kent Publishing: Boston, MA, 2004.
57. SAS Institute Inc.. SAS/STAT User's Guide, Version 8. SAS Institute Inc.: Cary, NC, 2000.
58. Kathiresan S, Larson MG, Benjamin EJ et al. Clinical and genetic correlates of serum aldosterone in the community: the Framingham Heart Study. Am J Hypertens 2005; 18(5 Part 1): 657-665.